Reactive Mesothelial Hyperplasia

A benign, non-cancerous overgrowth of the mesothelial cells that line the pleura (around the lungs), peritoneum (in the abdomen), and pericardium (around the heart). It occurs when these cells multiply in response to inflammation, infection, surgery, fluid buildup, or chemical irritation. Because the proliferating cells can look strikingly similar to malignant mesothelioma under the microscope, distinguishing the two is one of the hardest problems in pathology and a frequent flashpoint in asbestos litigation.

Origin

"Reactive" derives from the Latin reagere, to respond. "Mesothelial" combines the Greek mesos (middle) and thele (covering), referring to the cell layer lining the body's serous cavities. "Hyperplasia" is from the Greek hyper (over) and plasis (formation). The diagnostic category came into wide use in the mid-20th century as pathologists began systematically separating benign from malignant mesothelial proliferations.

Significance in Asbestos Context

For patients, this diagnosis matters in several practical ways. First, it is a common point of disagreement between pathologists: a defense expert may label your tissue "reactive" while your own expert reads it as early or invasive mesothelioma. Second, modern testing has made this distinction more objective. Loss of the BAP1 protein on immunohistochemistry and deletion of the p16/CDKN2A gene on FISH testing strongly favor malignancy, while their absence is more consistent with a reactive process. Third, an initial reactive diagnosis does not rule out mesothelioma; biopsies can under-sample tumor, and what looks reactive today may be recognized as cancer on a later biopsy. Finally, asbestos bankruptcy trusts and most lawsuits require a confirmed malignant diagnosis, so getting the pathology right is essential to both your treatment and any potential claim.

Example Sentence

After the first biopsy was read as reactive mesothelial hyperplasia, the patient's oncologist sent the slides to a mesothelioma specialty center, where BAP1 immunohistochemistry and FISH testing for p16 deletion ultimately confirmed epithelioid mesothelioma.

Related Terms

Mesothelioma, Immunohistochemistry (IHC), BAP1, FISH Testing, p16/CDKN2A Deletion, Pleural Effusion, Epithelioid Mesothelioma, Cytology

Notes

• If you have an asbestos exposure history and received a reactive mesothelial hyperplasia diagnosis, request a second opinion from a mesothelioma-specialized pathologist (such as at an NCI-designated cancer center or a mesothelioma program like those at Penn, MD Anderson, Brigham and Women's, or UCLA) before accepting the result as final.
• Ask specifically whether BAP1 immunohistochemistry and FISH testing for p16/CDKN2A deletion were performed. These are the two most important objective tests for separating reactive change from malignancy and are not always done on the first pass.
• Make sure your paraffin tissue blocks and unstained slides are preserved by the pathology lab. These materials are needed for any future re-review, additional staining, or expert examination in litigation, and labs typically retain blocks for a limited period.
• Maintain regular imaging follow-up (usually CT scans) with your physician even if the diagnosis remains benign, because mesothelioma can emerge months or years later from tissue that initially looked reactive.
• Document and preserve your asbestos exposure history (jobs, products, dates, witnesses) now, even before a malignant diagnosis is made, and speak with an asbestos attorney about protecting statutes of limitations. These can begin to run from the date of certain non-malignant findings in some states.
• Be aware that non-asbestos causes (recent thoracic surgery, pleurodesis, infection (including tuberculosis), pulmonary embolism, and dialysis-related peritonitis) can also trigger reactive hyperplasia and may be raised by the defense as alternative explanations.